We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bitter pill

31 March 2021 By Gina Chon

The U.S. Federal Trade Commission wants to block Illumina’s $7.1 bln purchase of cancer-testing outfit Grail. Preventing the gene-sequencing group from reabsorbing a company it spun out in 2017 shows that watchdogs’ tougher thinking about competition is turning into action.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)